Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 10/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 10/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 10/20 | 0.35 |
| ▸ | FGFR3 | P22607 | 10/20 | 0.35 |
| ▸ | KDR | P35968 | 8/20 | 0.35 |
| ▸ | VCP | P55072 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SORD | Q00796 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8142536 | 0.76 | TSHR (0.48) | ALDH1A1FGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL4215152 | 0.74 | SORD (0.42) | ALDH1A1FGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL20309635 | 0.74 | KDM4E (0.37) | ALDH1A1FGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL4200809 | 0.74 | KDM4E (0.37) | ALDH1A1FGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL14334526 | 0.73 | FGFR1 (0.40) | SMN1; SMN2FGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL2126277 | 0.73 | KDM4E (0.36) | ALDH1A1FGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL8142567 | 0.73 | SMN1; SMN2 (0.47) | ALDH1A1SMN1; SMN2FGFR1FGFR2FGFR4 | |
| SCHEMBL21178480 | 0.72 | MAP4K4 (0.46) | LMNASMN1; SMN2VCP | |
| SCHEMBL6428241 | 0.72 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2KDM4EGAA | |
| SCHEMBL4068129 | 0.72 | KDM4E (0.36) | ALDH1A1FGFR1FGFR2FGFR4FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370533-B1 | IMIDIAZOLE DERIVATIVES AND THEIR USE AS AGONISTS SELECTIVE AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS | ALLERGAN INC (US) | 2015-05-06 | — | — | EP | disclosed |
| US-6841684-B2 | For therapy of chronic pain, glaucoma or elevated intraocular pressure and other diseases with substantially reduced cardiovascular or sedative side effects | ALLERGAN, INC. (US) | 2005-01-11 | — | — | US | disclosed |
| EP-1036065-B1 | SUBSTITUTED IMIDAZOLE DERIVATIVES HAVING AGONIST-LIKE ACTIVITY AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS | ALLERGAN INC (US) | 2004-05-12 | — | — | EP | disclosed |
| EP-1370533-A2 | IMIDIAZOLE DERIVATIVES AND THEIR USE AS AGONISTS SELECTIVE AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS | Allergan, Inc. (US) | 2003-12-17 | — | — | EP | disclosed |
| US-20030023098-A1 | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors | ALLERGAN SALES, INC. | 2003-01-30 | — | — | US | disclosed |
| US-20020156076-A1 | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B / 2C adrenergic receptors | ALLERGAN SALES, INC. | 2002-10-24 | — | — | US | disclosed |
| WO-2002076950-A2 | IMIDIAZOLE DERIVATIVES AND THEIR USE AS AGONISTS SELECTIVE AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS | ALLERGAN, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| US-6329369-B1 | ANALGESICS FOR TREATING GLAUCOMA OR ELEVATED PRESSURE AND OTHER DISEASES WITH REDUCED SIDE EFFECTS BY TREATING A MAMMAL IN NEED THEREOF AN AGONIST OF ALPHA 2B OR ALPHA 2B/2C ADRENERGIC RECEPTOR | ALLERGAN SALES, INC. | 2001-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030023098-A1 | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors | ADRA2B, ADRB2, ADRA2C | ALDH1A1 769/4885LMNA 1706/4885SMN1; SMN2 2593/4885 |
| US-20020156076-A1 | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B / 2C adrenergic receptors | ADRB2, ADRB1, ADRA2B | ALDH1A1 1129/4885LMNA 763/4885SMN1; SMN2 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.